Ask AI
ProCE Banner Activity

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Slideset

Download these slides from a recent live webinar on how menin inhibitors are currently being used in AML management to personalize treatment and improve patient outcomes based on evidence from key clinical trials.

Released: January 22, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson, Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc. 

Johnson & Johnson

Kura Oncology, Inc.

Syndax Pharmaceuticals, Inc.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients and colleagues on the mechanisms of action for menin inhibitors and the clinical rationale for inhibiting menin in AML

  • Plan individualized treatments leveraging approved or investigational menin inhibitors for patients with relapsed/refractory AML harboring KMT2A rearrangements or NPM1 mutations based on the latest evidence, expert recommendations, and patient-/disease-specific factors

  • Apply evidence-based strategies to mitigate and manage differentiation syndrome related to menin inhibitors in patients with AML